ArticleCommunications biology2025
Target gene mutation discovery and amplicon sequencing for evaluating maduramicin resistance in Eimeria tenella.
Article in Communications biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Anticoccidial drug resistance in Eimeria spp. presents a growing threat to global poultry health and food security, necessitating robust molecular tools for resistance surveillance. In this study, we report the identification and functional validation of a single nucleotide mutation (c.1255 C > T) in the ETH2_0402100 gene of Eimeria tenella that confers resistance to maduramicin, a widely used ionophore anticoccidial drug. Using genetic crossing, backcrossing, and QTL-seq, we narrowed the resistance locus to a 76 kb region on chromosome HG994964.1. CRISPR/Cas9-mediated site-directed mutagenesis and gene overexpression confirmed that the leucine-to-phenylalanine substitution in ETH2_0402100 confers maduramicin resistance. To translate this discovery into a practical tool, we developed a PCR-based amplification sequencing assay that enables rapid, quantitative detection of maduramicin-resistant alleles from field samples. Together, these findings establish the molecular basis and monitoring strategy for maduramicin resistance in Eimeria spp., and provide a field-deployable molecular diagnostic tool for detecting ionophore resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.